Since December 2011, temporary reimbursement is granted for a minimum of two years
renewable for another year (before December 2011 agreements were concluded for a
minimum 1 year renewable on an annual basis for up to 3 years). To renew an agreement,
the manufacturer needs to submit a request to SÚKL. Extension is granted if insufficient data
on the drugs innovativeness have been collected to take a final reimbursement decision.